Key Message
New drugs are coming to the market and effective ART is available, yet toxicity issues and harmful outcomes during pregnancy, including major congenital anomalies, preterm delivery, anemia, and low birth weight, are of increasing concern among clinicians and program managers. In the development of either WHO or National ARV guidelines, clinical management of patients therefore, careful consideration should be taken in the inclusion of PI-based inhibitors, integrase inhibitors, Zidovudine, and newer drugs. Establishing a congenital anomalies surveillance system is recommended.
Citations
Citations to this article as recorded by
- Fifteen-minute consultation: How to approach the initial discussions of dysmorphism with parents
Kate Frances Parmenter, Sharon English, Jennifer Campbell
Archives of disease in childhood - Education & practice edition.2024; 109(4): 174. CrossRef - Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non‐case study from the global pharmacovigilance database VigiBase®
Laura Saint‐Lary, Isabelle Lacroix, Valériane Leroy, Agnès Sommet
Pharmacology Research & Perspectives.2024;[Epub] CrossRef - Understanding clinical outcome measures reported in HIV pregnancy studies involving antiretroviral-naive and antiretroviral-experienced women
Ahizechukwu C Eke, Rahel D Gebreyohannes, Anna M Powell
The Lancet Infectious Diseases.2023; 23(4): e151. CrossRef